A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is
With Transcatheter Aortic Valve Replacement (TAVR) revolutionizing the treatment of high-surgical risk patients with severe aortic stenosis, Transcatheter Mitral Valve Replacement (TMVR) is slowly emerging as an off-label therapy for severe mitral valve disease. The case of a 70-year-old female with recurrent history of congestive heart failure has been described. This case demonstrates the simultaneous TAVR and off-label VIV TMVR is a reasonable alternative for highrisk surgical patients with stenotic native and failing bioprosthetic valves.doi:10.21767/2471-8157.100060 fatcat:7gbzvuns7nhxvjyayi7w5qg7mi